Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | Director · President and CEO | May 06, 2020 | May 08, 2020 |
| EAGLE PHARMACEUTICALS, INC.EGRX · Entity 85958 | Director | March 07, 2023 | March 09, 2023 |
| LadRx CorpLADX · Entity 94858 | Director | January 15, 2024 | January 29, 2024 |
| Panbela Therapeutics, Inc.PBLA · Entity 11460 | Director · President and CEO | October 01, 2024 | October 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DELCATH SYSTEMS, INC.
Report date May 06, 2020 · Filed May 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,021 |
Last balance in matching sequence
After 2020-05-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-05-06 · Grant · Acquired 10,310 · Balance 10,321 F2: Reflects a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019. Row 2 · 2020-05-08 · Conversion · Acquired 14,700 · Balance 25,021 F1: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. F2: Reflects a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019. |
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-08 · Conversion · Disposed 147 · Balance 0 F1: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00.
F2: Reflects a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019.
EAGLE PHARMACEUTICALS, INC.
Report date March 07, 2023 · Filed March 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.00 · Expires 2033-03-07 | Direct | 16,253 |
Reported balance
After 2023-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-07 · Grant · Acquired 16,253 · Balance 16,253 F1: The option fully vests on March 7, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vests on March 7, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.
LadRx Corp
Report date January 15, 2024 · Filed January 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2034-01-14 | Direct | 5,000 |
Reported balance
After 2024-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-15 · Grant · Acquired 5,000 · Balance 5,000 F1: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant.
Panbela Therapeutics, Inc.
Report date October 01, 2024 · Filed October 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2034-10-01 | Direct | 72,800 |
Reported balance
After 2024-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-01 · Grant · Acquired 72,800 · Balance 72,800 F1: The option fully vests on October 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vests on October 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2024 Filed Oct 3, 2024 16:25 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantStock Option (right to buy) · Derivative | 72,800 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001437749-24-030616 · rdgdoc.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,800 Underlying: Common Stock · 72,800 shares Expires 2034-10-01 F1 · derivative.exercise_date: The option fully vests on October 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| January 15, 2024 Filed Jan 29, 2024 16:05 UTC | LadRx Corp LADX · Entity 94858 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001493152-24-004139 · ownership.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-01-14 F1 · derivative.exercise_date: The stock options vested 50% on the date of grant and the remainder vests in substantially equal installments each month for a period of three (3) years from the date of grant. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:26 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantStock Option (right to buy) · Derivative | 99,383 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-23-008422 · rdgdoc.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,383 Underlying: Common Stock · 99,383 shares Expires 2033-03-27 F1 · derivative.exercise_date: The option fully vests on March 20, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:02 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 16,253 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017705 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,253 Underlying: Common Stock · 16,253 shares Expires 2033-03-07 F1 · derivative.exercise_date: The option fully vests on March 7, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:37 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | PurchaseWarrants (right to buy) · Derivative | 8,888 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001437749-23-002264 · rdgdoc.xml · derivative · entry 2 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2028-01-30 F2 · derivative.exercise_price: On or after March 1, 2023, holder may elect an "alternative cashless exercise" pursuant to which they would receive an aggregate number of shares of common stock equal to 75% of the aggregate number of shares that would be issuable upon a cash exercise. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:37 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | PurchaseCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002264 · rdgdoc.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,868 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase two shares of common stock for a combined price of $2.25 per share and warrant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:05 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 11,200 | $0.00 Strike: $47.39 | $0.00 |
DisclosureSEC source: 0001209191-22-015017 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Common Stock · 11,200 shares Expires 2032-02-28 F1 · derivative.exercise_date: The option fully vests on February 28, 2023, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 10:08 UTC | LadRx Corp CYTR · Entity 94858 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-031814 · ownership.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| December 15, 2021 Filed Jan 11, 2022 21:35 UTC Amendment | LadRx Corp CYTR · Entity 94858 | GrantStock Appreciation Right · Derivative | 50,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001493152-22-000985 · ownership.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · security: The purpose of this Amendment is to report the stock appreciation rights granted to the reporting person on December 15, 2021, which were inadvertently excluded from the original Form 4. The stock appreciation rights will vest in full on the first anniversary of December 15, 2021, provided that the reporting person is still a service provider of CytRx Corporation on such date. F2 · derivative.expiration_date: No expiration date. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:00 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 19,125 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001437749-21-022213 · rdgdoc.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,125 Underlying: Common Stock · 19,125 shares Expires 2031-09-13 F1 · derivative.exercise_date: The stock option is schedule to vest in three equal annual installments on September 13, 2022, 2023 and 2024. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 09:33 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001437749-21-007952 · rdgdoc.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2031-03-30 F1 · derivative.exercise_date: The stock option is exercisable in three substantially equal installments on the first, second and third anniversaries of the date of grant (March 30, 2022, 2023 and 2024). Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:21 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $49.32 | $0.00 |
DisclosureSEC source: 0001209191-21-007818 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2031-02-02 F1 · derivative.exercise_date: The option fully vests on February 2, 2022, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 17:52 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseCommon Stock | 1,000 | $2.74 | $2,737.10 |
DisclosureSEC source: 0001437749-20-019686 · rdgdoc.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,424 Read SEC document |
| September 01, 2020 Filed Sep 1, 2020 17:47 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseWarrant (right to buy) · Derivative | 2,424 | Not disclosed Strike: $4.54 | Not disclosed |
DisclosureSEC source: 0001437749-20-019143 · rdgdoc.xml · derivative · entry 2 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 Underlying: Common Stock · 2,424 shares Expires 2025-09-01 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $4.125 per share and warrant. Read SEC document |
| September 01, 2020 Filed Sep 1, 2020 17:47 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseCommon Stock | 2,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-019143 · rdgdoc.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $4.125 per share and warrant. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:22 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 212,048 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001437749-20-015352 · rdgdoc.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,048 Underlying: Common Stock · 212,048 shares Expires 2030-07-15 F1 · derivative.exercise_date: Immediately exercisable as to 25% of the shares and scheduled to vest with respect to 25% of the shares on each of July 15, 2021, July 15, 2022 and July 15, 2023. Read SEC document |
| May 08, 2020 Filed May 8, 2020 23:21 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | ConversionSeries E Convertible Preferred Stock · Derivative | 147 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012462 · doc4.xml · derivative · entry 3 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. F1 · derivative.exercise_date: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. F1 · derivative.expiration_date: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. F1 · derivative.underlying_shares: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. Read SEC document |
| May 08, 2020 Filed May 8, 2020 23:21 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | ConversionCommon Stock | 14,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012462 · doc4.xml · nonDerivative · entry 2 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Series E Convertible Preferred Stock has no expiration date and a stated value of $1,000 (the "Stated Value"). On May 8, 2020, reporting person converted the Series E Preferred Stock into that number of shares of Delcath Systems Inc. common stock determined by dividing the Stated Value by the conversion price of $10.00. F2 · balance_after: Reflects a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019. Read SEC document |
| May 06, 2020 Filed May 8, 2020 23:21 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantCommon Stock | 10,310 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012462 · doc4.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,321 F2 · balance_after: Reflects a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:27 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $59.80 | $0.00 |
DisclosureSEC source: 0001209191-20-002356 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-04 F1 · derivative.exercise_date: The option fully vests on January 5, 2021, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 08:02 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001209191-19-052905 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-10-08 F1 · derivative.exercise_date: The option vests over a period of three years, in 36 equal monthly installments commencing on the one-month anniversary of August 28, 2019, subject to the Reporting Person's continuous service with the Issuer as of the vesting date Read SEC document |
| July 15, 2019 Filed Jul 27, 2019 01:29 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 2,450,000 | Not disclosed Strike: $0.06 | Not disclosed |
DisclosureSEC source: 0000899243-19-020494 · doc4.xml · derivative · entry 2 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,450,000 Underlying: Common Stock · 2,450,000 shares Expires not disclosed F3 · derivative.exercise_price: The warrant was included together with the purchase of Series E Convertible Preferred Stock purchased by the reporting person for $1,000 per share. The purchase of shares of Series E Convertible Preferred Stock was accompanied by a right to purchase 16,666.67 shares of common stock for an aggregate of 2,450,000 shares of common stock. The exercise price of each share under the warrant is $0.06, subject to adjustment in accordance with the terms of the warrant and is exercisable at any time from the date that the issuer effects a reverse stock split through 5:00 p.m. (NYC time) on the fifth anniversary of the date of the reverse stock split. F2 · kind: The purchase was made in a private (PIPE) transaction with the issuer in which the issuer sold Series E Convertible Preferred Stock and warrants. The transactions contemplated by the PIPE transaction were reported on a current report on Form 8-K filed with the SEC by the issuer on each of July 11, 2019 and July 22, 2019. F3 · price: The warrant was included together with the purchase of Series E Convertible Preferred Stock purchased by the reporting person for $1,000 per share. The purchase of shares of Series E Convertible Preferred Stock was accompanied by a right to purchase 16,666.67 shares of common stock for an aggregate of 2,450,000 shares of common stock. The exercise price of each share under the warrant is $0.06, subject to adjustment in accordance with the terms of the warrant and is exercisable at any time from the date that the issuer effects a reverse stock split through 5:00 p.m. (NYC time) on the fifth anniversary of the date of the reverse stock split. F3 · derivative.exercise_date: The warrant was included together with the purchase of Series E Convertible Preferred Stock purchased by the reporting person for $1,000 per share. The purchase of shares of Series E Convertible Preferred Stock was accompanied by a right to purchase 16,666.67 shares of common stock for an aggregate of 2,450,000 shares of common stock. The exercise price of each share under the warrant is $0.06, subject to adjustment in accordance with the terms of the warrant and is exercisable at any time from the date that the issuer effects a reverse stock split through 5:00 p.m. (NYC time) on the fifth anniversary of the date of the reverse stock split. F3 · derivative.expiration_date: The warrant was included together with the purchase of Series E Convertible Preferred Stock purchased by the reporting person for $1,000 per share. The purchase of shares of Series E Convertible Preferred Stock was accompanied by a right to purchase 16,666.67 shares of common stock for an aggregate of 2,450,000 shares of common stock. The exercise price of each share under the warrant is $0.06, subject to adjustment in accordance with the terms of the warrant and is exercisable at any time from the date that the issuer effects a reverse stock split through 5:00 p.m. (NYC time) on the fifth anniversary of the date of the reverse stock split. Read SEC document |
| July 15, 2019 Filed Jul 27, 2019 01:29 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseSeries E Convertible Preferred Stock · Derivative | 147 | $1,000.00 Strike: $0.06 | $147,000.00 |
DisclosureSEC source: 0000899243-19-020494 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 Underlying: Common Stock · 2,450,000 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Series E Convertible Preferred Stock, par value of $0.01 per share, has a stated value of $1,000 (the "Stated Value") and is convertible at any time at the option of the holder into the number of shares of Delcath common stock determined by dividing the Stated Value by the conversion price of $0.06, subject to certain limitations and adjustments contemplated within the Certificate of Designation. F2 · kind: The purchase was made in a private (PIPE) transaction with the issuer in which the issuer sold Series E Convertible Preferred Stock and warrants. The transactions contemplated by the PIPE transaction were reported on a current report on Form 8-K filed with the SEC by the issuer on each of July 11, 2019 and July 22, 2019. F1 · derivative.exercise_date: Each share of the Series E Convertible Preferred Stock, par value of $0.01 per share, has a stated value of $1,000 (the "Stated Value") and is convertible at any time at the option of the holder into the number of shares of Delcath common stock determined by dividing the Stated Value by the conversion price of $0.06, subject to certain limitations and adjustments contemplated within the Certificate of Designation. F4 · derivative.expiration_date: The Series E Convertible Preferred Stock has no expiration date. F3 · derivative.underlying_shares: The warrant was included together with the purchase of Series E Convertible Preferred Stock purchased by the reporting person for $1,000 per share. The purchase of shares of Series E Convertible Preferred Stock was accompanied by a right to purchase 16,666.67 shares of common stock for an aggregate of 2,450,000 shares of common stock. The exercise price of each share under the warrant is $0.06, subject to adjustment in accordance with the terms of the warrant and is exercisable at any time from the date that the issuer effects a reverse stock split through 5:00 p.m. (NYC time) on the fifth anniversary of the date of the reverse stock split. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 02:02 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Options · Derivative | 350,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-19-002727 · doc4.xml · derivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · Director, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The stock options vest in equal amounts of 29,166 options for 11 consecutive months commencing on the one month anniversary of the grant date, and the balance of the options (29,174) vesting on the 12 month anniversary of the grant date. Options are immediately exercisable upon vesting. Read SEC document |
| September 28, 2018 Filed Oct 23, 2018 20:16 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCOMMON STOCK | 7,399 | $1.75 | $12,948.25 |
DisclosureSEC source: 0000899243-18-027290 · doc4.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 23:01 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 100 | $2.55 | $255.00 |
DisclosureSEC source: 0000899243-18-021260 · doc4.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101 Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | Tax withholdingCommon Stock | 468 | $0.22 | $101.70 |
DisclosureSEC source: 0000899243-17-017527 · doc4.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,908 F1 · kind: Represents shares withheld and disposed of by the issuer's equity plan administrator to satisfy withholding taxes due in connection with the vesting of shares underlying a previously disclosed equity award. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 21:21 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003466 · doc4.xml · nonDerivative · entry 1 Simpson Jennifer K. · CIK 0001545253 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,376 F1 · security: Consists of a restricted share award. The shares are subject to vesting on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.